Abstract:Combating influenza is one of the perennial global public health issues to be managed. Antiviral drugs are useful for the treatment of influenza in the absence of an appropriate vaccine. However, the appearance of resistant strains necessitates a constant search for new drugs. In this study, we investigated novel anti-influenza drug candidates using in vitro and in vivo assays. We identified anti-influenza hit compounds using a high-throughput screening method with a green fluorescent protein-tagged recombinant influenza virus. Through subsequent analyses of their cytotoxicity and pharmacokinetic properties, one candidate (IY7640) was selected for further evaluation. In a replication kinetics analysis, IY7640 showed greater inhibitory effects during the early phase of viral infection than the viral neuraminidase inhibitor oseltamivir. In addition, we observed that hemagglutinin (HA)-mediated membrane fusion was inhibited by IY7640 treatment, indicating that the HA stalk region, which is highly conserved across various (sub)types of influenza viruses, may be the molecular target of IY7640. In an escape mutant analysis in cells, amino acid mutations were identified at the HA stalk region of the 2009 pandemic H1N1 (pH1N1) virus. Even though the in vivo efficacy of IY7640 did not reach complete protection in a lethal challenge study in mice, these results suggest that IY7640 has potential to be developed as a new type of anti-influenza drug.IMPORTANCE Anti-influenza drugs with broad-spectrum efficacy against antigenically diverse influenza viruses can be highly useful when no vaccines are available. To develop new anti-influenza drugs, we screened a number of small molecules and identified a strong candidate, IY7640. When added at the time of or after influenza virus infection, IY7640 was observed to successfully inhibit or reduce viral replication in cells. We subsequently discovered that IY7640 targets the stalk region of the influenza HA protein, which exhibits a relatively high degree of amino acid sequence conservation across various (sub)types of influenza viruses. Furthermore, IY7640 was observed to block HA-mediated membrane fusion of H1N1, H3N2, and influenza B viruses in cells. Although it appears less effective against strains other than H1N1 subtype viruses in a challenge study in mice, we suggest that the small molecule IY7640 has potential to be optimized as a new anti-influenza drug.

Screening of Potent Inhibitor of H1N1 Influenza NS1 CPSF30 Binding Pocket by Molecular Docking

Ligand-based Dual Target Drug Design for H1N1: Swine Flu--a Preliminary First Study.

Identification of a Small-Molecule Inhibitor of Influenza Virus Via Disrupting the Subunits Interaction of the Viral Polymerase.

Binding Mechanism of H5N1 Influenza Virus Neuraminidase with Ligands and Its Implication for Drug Design

Drug design for Influenza A virus subtype H1N1

Screening from the World'S Largest Tcm Database Against H1n1 Virus

Molecular Dynamics Analysis of Potent Inhibitors of M2 Proton Channel Against H1N1 Swine Influenza Virus

Virtual Screening and Molecular Dynamics Simulation Study of Influenza Polymerase PB2 Inhibitors

Novel Hemagglutinin Inhibitors for H1N1 Influenza Virus Screening from TCM Database

Identification of Novel Influenza Polymerase PB2 Inhibitors Using a Cascade Docking Virtual Screening Approach

Residue-based Design of Small Molecule Inhibitor for H1N1, H5N1 and H7N1 Mutants

Implications of protein conformations to modifying novel inhibitor Oseltamivir for 2009 H1N1 influenza A virus by simulation and docking studies

Potent Inhibitor Design Against H1N1 Swine Influenza: Structure-Based and Molecular Dynamics Analysis for M2 Inhibitors from Traditional Chinese Medicine Database.

Identification of Influenza PAN Endonuclease Inhibitors via 3D-QSAR Modeling and Docking-Based Virtual Screening

Rational Design of Tamiflu Derivatives Targeting at the Open Conformation of Neuraminidase Subtype 1

Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses

Prediction and characterization of influenza virus polymerase inhibitors through blind docking and ligand based virtual screening

Theoretical Studies on the Susceptibility of Oseltamivir Against Variants of 2009 A/H1N1 Influenza Neuraminidase.

Identification of the Imidazo[1,2- a]pyrazine Derivative A4 as a Potential Influenza Virus Nucleoprotein Inhibitor

Design, Synthesis and Biological Evaluation of "Multi-Site"-binding Influenza Virus Neuraminidase Inhibitors.

Computational screening of known broad-spectrum antiviral small organic molecules for potential influenza HA stem inhibitors